{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:54:14Z","timestamp":1788317654707,"version":"build-2803163510"},"reference-count":42,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2020-PT310-01"],"award-info":[{"award-number":["2020-PT310-01"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) is linked to exaggerated gamma oscillations. Buspirone, a 5-HT1A receptor agonist, is a potent medication for psychiatric conditions, predominantly prescribed for anxiety treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to investigate whether buspirone alleviates dyskinesia in LID rat and its effects on pathological oscillatory activity and cortico-striatal functional connectivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected motor behavior and electrophysiological data of cortico-striatal from Sham rats, unilateral 6-hydroxydopamine (6-OHDA)-lesioned PD model rats, and rats with LID. We further examined the behavioral and electrophysiological changes in LID rats following buspirone intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PD rats showed increased beta activity and aperiodic components at 10\u201350\u2005Hz, while LID rats exhibited excessive gamma oscillations and aperiodic activity at 50\u2013150\u2005Hz. Additionally, gamma-band functional connectivity within the cortico-striatal circuit was significantly enhanced during on-state dyskinesia, when rats exhibited abnormal involuntary movements. Administration of buspirone effectively reduced dyskinesia severity, suppressed gamma activity, decreased aperiodic components (50\u2013150\u2005Hz), and disrupted gamma-band functional connectivity without compromising the antiparkinsonian effects of levodopa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Excessive gamma oscillations represent a key electrophysiological marker of dyskinesia. Altered gamma-band connectivity within the cortico-striatal network may contribute to its pathophysiology. Buspirone appears to be a promising candidate for the treatment of LID, potentially offering a novel therapeutic strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x251380196","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:36:02Z","timestamp":1759851362000},"page":"1367-1382","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Buspirone regulates cortico-striatal gamma oscillations to ameliorate dyskinesia"],"prefix":"10.1177","volume":"15","author":[{"given":"Han","family":"Liu","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"NHC Key Laboratory of Prevention and treatment of Cerebrovascular Disease, Henan Key Laboratory of Cerebrovascular Diseases of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"NHC Key Laboratory of Prevention and treatment of Cerebrovascular Disease, Henan Key Laboratory of Cerebrovascular Diseases of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2689-9897","authenticated-orcid":false,"given":"Yuming","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"NHC Key Laboratory of Prevention and treatment of Cerebrovascular Disease, Henan Key Laboratory of Cerebrovascular Diseases of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Dai","sequence":"additional","affiliation":[{"name":"School of Basic Medical Science, Sanquan College of Xinxiang Medical University, XinXiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-2484","authenticated-orcid":false,"given":"Pengfei","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Department of Otology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00218-X"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad388"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01478-2"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001166"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01309-5"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.12.027"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad206"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105397"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad273"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.962957"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1128-16.2016"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.320984"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-020-00606-3"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14241"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01644-2"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29102184"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-240080"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.6b00440"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.5.845"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105507"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2024.114833"},{"key":"e_1_3_4_23_2","article-title":"The dosage of curcumin to alleviate movement symptoms in a 6-hydroxydopamine-induced Parkinson's disease rat model","volume":"9","author":"Liu X","year":"2023","unstructured":"Liu X, Zhang H, Li C, et al. The dosage of curcumin to alleviate movement symptoms in a 6-hydroxydopamine-induced Parkinson's disease rat model. Heliyon 2023; 9: e16921.","journal-title":"Heliyon"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26581"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.85711"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.01.017"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-020-00744-x"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-23-01240"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100825"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1953-19.2019"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109696"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2016.05.007"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0357-20.2020"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29276"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-023-01041-8"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2017.00024"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26674"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.943179"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26291"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107997"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2018.01.010"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15145"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28403"}],"updated-by":[{"DOI":"10.1177\/1877718x251408974","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000}}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251380196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X251380196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251380196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:40:02Z","timestamp":1780684802000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X251380196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/1877718X251380196"],"URL":"https:\/\/doi.org\/10.1177\/1877718x251380196","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}